|

Golimumab Clinical Trials

3 actively recruiting trials across 3 locations

Also known as: CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer, Simponi

Pipeline

Phase 2: 1Phase 3: 2

Top Sponsors

  • University of Washington1
  • University of Pennsylvania1
  • University of Nebraska1

Indications

  • Arthritis2
  • Psoriatic Arthritis1
  • Metastatic Castration-Resistant Prostate Carcinoma1
  • Rheumatoid Arthritis1
  • Stage IV Prostate Cancer AJCC v81

Loxahatchee Groves, Florida1 trial

Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients

Family Arthritis Center

Phase 3

Omaha, Nebraska1 trial

Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

University of Nebraska Medical Center

Phase 3

Seattle, Washington1 trial

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.